Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Licenses Polypeptide Nanoparticle Delivery Technology from University of Maryland Medical School

Premium

Sirnaomics said this week that it has licensed a polypeptide nanoparticle delivery technology developed at the University of Maryland Medical School.

"The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of histidine-lysine polymer for siRNA therapeutics in the areas of wound healing and ocular diseases," the company said.

"Licensing the histidine-lysine polymer nanoparticle technology is rooted in our long-time experience and in-depth understanding of this unique class of polypeptides as an siRNA delivery vehicle," Sirnaomics President and CEO Patrick Lu said in a statement. "We are currently engaging in several similar collaborative efforts and we believe that this is a great way to create value and ensure the credibility of a novel technology."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.